Skip to main content

INDV 6-K

Indivior Pharmaceuticals, Inc. (INDV)

6-K 2025-01-21 For: 2025-01-21
View Original
Added on April 10, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

________________________

Washington, D.C. 20549

_____________________

FORM 6-K

_____________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2025

Commission File Number: 001-37835

________________________________________

Indivior PLC

________________________________________

10710 Midlothian Turnpike, Suite 125

North Chesterfield, Virginia 23235

(Address of principal executive office)

_______________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit No. Description of Exhibit
99.1 Announcement sent to the London Stock Exchange on January 21, 2025,<br>titled “Transaction in Own Shares”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Indivior PLC
Date: January 21,<br>2025 /s/<br>Kathryn Hudson
Name:<br>Kathryn Hudson
Title:<br>Company Secretary

a0072u-announcement

Exhibit 99.1

INDIVIOR PLC

SHARE REPURCHASE PROGRAM

WEEKLY REPORT

January 21, 2025

INDIVIOR PLC ("Indivior") announces that it purchased for cancellation a total of 222,704 of its ordinary shares of $0.50 each through Morgan Stanley & Co. International Plc in the period from January 13, 2025, up to and including January 17, 2025, in connection with its $100m Share Repurchase Program. Aggregated information on the purchase of these shares can be found in the table below.

Following the purchase and cancellation of the above shares (including those purchased but not yet settled), Indivior has 124,440,149 ordinary shares of $0.50 each with voting rights in issue. There are no shares held in treasury.

The above figure (124,440,149) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Indivior under the FCA's Disclosure Guidance and Transparency Rules.

All repurchases by Indivior are "On Exchange" transactions (as such term is defined in the rules of the London Stock Exchange) and "on market" for the purposes of the Companies Act 2006.

Aggregated information

Trading Date Trading Venue Aggregated daily volume (number of shares) Daily weighted average purchase price of the shares<br>(p)
13/01/2025 LSE 13,156 949.06
13/01/2025 BATE 5,768 950.46
13/01/2025 CHIX 19,243 952.86
13/01/2025 AQUIS 1,894 953.41
14/01/2025 LSE 29,621 929.64
14/01/2025 BATE 8,881 928.88
14/01/2025 CHIX 21,561 936.26
14/01/2025 AQUIS 3,002 935.82
15/01/2025 LSE 15,395 935.82
15/01/2025 BATE 5,658 938.35
15/01/2025 CHIX 17,464 938.32
15/01/2025 AQUIS 2,530 937.60
16/01/2025 LSE 12,350 948.47
16/01/2025 BATE 6,014 943.90
16/01/2025 CHIX 19,525 945.43
16/01/2025 AQUIS 1,439 944.66
17/01/2025 LSE 14,284 961.68
17/01/2025 BATE 5,179 968.51
17/01/2025 CHIX 17,462 964.78
17/01/2025 AQUIS 2,278 962.97

Transaction details

In accordance with Article 5(1)(b) of the assimilated Market Abuse Regulation (EU) No 596/2014, as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018 and Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual purchases of ordinary shares made by Morgan Stanley & Co. International Plc on behalf of Indivior during the above period as part of the Share Repurchase Program can be found at www.indivior.com/en/investors/shareholder-information/share-repurchase-program.

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

Contact:

Jason Thompson

Vice President, Investor Relations

1-804-402-7123